Adaptive enrichment trials: What are the benefits?

Area of Science:

• Clinical Trial Design
• Biostatistics
• Pharmaceutical Research

Background:

• Phase III clinical trials often involve heterogeneous patient populations.
• A subset of patients may exhibit a superior response to a novel treatment.
• Traditional trial designs may not optimally leverage this information during the trial.

Purpose of the Study:

• To introduce adaptive enrichment designs for Phase III clinical trials.
• To develop a multiple testing procedure that controls the familywise error rate (FWER) under adaptive sampling.
• To derive the Bayes optimal rule for adaptive patient recruitment decisions.

Main Methods:

• Definition of a multiple testing procedure for adaptive enrichment.
• Derivation of the Bayes optimal rule for restricting recruitment based on interim data.
• Development of an efficient algorithm for simulation-based optimization of Bayes optimal rules.

Main Results:

• A statistically sound method is presented to maintain FWER control in adaptive enrichment trials.
• The study derives the optimal decision rule for adapting the target population post-interim analysis.
• Simulation-based optimization facilitates the construction of Bayes optimal rules across various scenarios.

Conclusions:

• Adaptive enrichment designs offer significant potential benefits over traditional nonadaptive designs.
• The proposed methodology enables efficient and statistically rigorous adaptive patient selection.
• This approach can optimize resource allocation and treatment effectiveness in clinical trials.